Measures of adherence in patients with severe asthma prescribed systemic steroids in the U-BIOPRED cohort

Alahmadi, Fahad; Simpson, Andrew; Gomez, Christina; Wheelock, Craig E.; Shaw, Dominick; Fleming, Louise; Roberts, Graham; Riley, John; Bates, Stewart; Knowles, Richard G.; Bansal, Aruna T.; Corfield, Julie; Pandis, Ioannis; Sun, Kai; Bakke, Per; Caruso, Massimo; Chanez, Pascal; Dahlén, B.; Horváth, Ildikó; Krug, Norbert; Montuschi, Paolo; Sandström, Thomas; Singer, Florian; Wagers, Scott; Adcock, Ian M.; Djukanović, Ratko; Chung, Kian Fan; Sterk, Peter J.; Dahlén, Sven‐Erik; Fowler, Stephen J.

doi:10.1183/13993003.congress-2018.pa3992

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A lahmadi et al. [ 17 ] presented data from the U-BIOPRED study with the aim of investigating the adherence of asthmatics according to the Medication Adherence Report Scale (MARS) and urinary tests. One third of asthmatics reported sub-optimal adherence, while 42% of the severe asthmatics did not have detectable urinary prednisolone or metabolites.…”

Section: Asthmamentioning

confidence: 99%

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

et al. 2019

View full text Add to dashboard Cite

The annual European Respiratory Society (ERS) International Congress (held in Paris in 2018) was once again a platform for discussion of the highest-quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses only some of the high-quality research studies presented at this year's Congress, with a particular focus on airway diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and cough, as presented through Assembly 5 of the ERS (Airway Diseases: Asthma and COPD). The authors establish the key take-home messages of these studies, compare their findings and place them in the context of current understanding.

show abstract

Section: Asthmamentioning

confidence: 99%

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The mainstay of asthma therapy has, for decades, included inhaled corticosteroids (ICS) for maintenance as well as shortacting beta-agonist (SABA) as-needed for rapid relief of acute symptoms. However, adherence to ICS monotherapy for asthma control is low [1][2][3], which may in part be due to the minimal perceived benefit of ICS for immediate symptom relief. And while SABA provides short-term relief of symptoms, frequent and prolonged use is associated with betareceptor tolerance and limits the efficacy of these agents, an effect, which is mitigated by concomitant steroid therapy [4], suggesting a synergy between SABA and ICS for asthma control.…”

Section: Introductionmentioning

confidence: 99%

As-needed inhaled corticosteroids as add-on therapy versus SMART therapy: an evolving understanding of the two approaches in the management of moderate-to-severe asthma

Salciccioli

Israel

2023

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of reviewAsthma is the most common chronic respiratory disorder, characterized by recurring, reversible airflow obstruction due to inflammation and airway hyperresponsiveness. Although biologics have provided significant advances in the treatment of asthma, they are expensive, and their use remains restricted to more severe asthma. Additional approaches in the management of moderate-to-severe asthma are necessary.Recent findings ICS--formoterol as maintenance and reliever therapy in asthma and its effect on improved asthma control has been demonstrated in multiple cohorts of asthma. Although ICS--formoterol as maintenance and reliever therapy has been widely validated, there are significant design considerations including the requirement for exacerbation and bronchodilator response and the lack of evidence for effectiveness in patients who use nebulized reliever therapies, which may limit the use of this therapy in selected populations. More recent trials of as-needed ICS have demonstrated effectiveness in reducing asthma exacerbations and improvements in asthma control and may provide an additional therapeutic strategy for individuals with moderate-to-severe asthma.

show abstract

Measures of adherence in patients with severe asthma prescribed systemic steroids in the U-BIOPRED cohort

Cited by 2 publications

References 0 publications

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

As-needed inhaled corticosteroids as add-on therapy versus SMART therapy: an evolving understanding of the two approaches in the management of moderate-to-severe asthma

Contact Info

Product

Resources

About